Amicus Therapeutics is a biopharmaceutical company developing oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. The Company is focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. Its technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to misfolded, unstable proteins caused by genetic mutations. It is initially targeting lysosomal storage disorders and continues to develop its pharmacological chaperone technology having built an intellectual property portfolio along with its robust clinical and preclinical pipeline.
Type | Public | |
Founded | 2002 | |
HQ | Philadelphia, PA, US | Map |
Website | amicusrx.com | |
Employee Ratings | ||
Overall Culture | C+ | More |
USD | |
---|---|
Revenue (Q1, 2021) | 66.4m |
Gross profit (Q1, 2021) | 59.9m |
Gross profit margin (Q1, 2021), % | 90.2% |
Net income (Q1, 2021) | (65.7m) |
EBIT (Q1, 2021) | (53.1m) |
Market capitalization (27-May-2022) | 2.2b |
Closing stock price (27-May-2022) | 7.9 |
Cash (31-Mar-2021) | 184.8m |
EV | 2.5b |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 4.0m | 5.8m | 7.8m | 10.6m | 39.0k | 456.0k | 475.0k | 293.0k | 2.1m | 4.2m | 7.2m | 10.9m | 16.7m | 21.3m | 20.6m | 34.0m | 44.1m | 48.8m | 60.5m | 62.4m | 67.4m | 66.4m | ||||||||
Cost of goods sold | 344.0k | 775.0k | 1.1m | 1.8m | 2.6m | 3.1m | 4.3m | 4.1m | 5.4m | 5.6m | 6.6m | 6.7m | 8.4m | 6.5m | ||||||||||||||||
Gross profit | 1.8m | 3.4m | 6.1m | 9.1m | 14.1m | 18.2m | 16.3m | 30.0m | 38.8m | 43.2m | 54.0m | 55.7m | 59.0m | 59.9m | ||||||||||||||||
Gross profit Margin, % | 84% | 81% | 85% | 84% | 84% | 85% | 79% | 88% | 88% | 89% | 89% | 89% | 88% | 90% |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 25.8m | 22.8m | 24.5m | 28.9m | 24.3m | 26.7m | 23.5m | 30.0m | 27.5m | 41.9m | 19.7m | 28.8m | 249.0m | 19.4m | 23.5m | 63.7m | 33.1m | 44.8m | 37.4m | 64.1m | 114.3m | 73.3m | 201.8m | 96.3m | 220.6m | 166.3m | 123.2m | 164.6m | 210.6m | 184.8m |
Accounts Receivable | 2.0m | 3.8m | 4.3m | 7.2m | 3.2m | 1.3m | 1.0m | 2.1m | 38.0k | 475.0k | 293.0k | 864.0k | 1.9m | 3.8m | 6.0m | 10.8m | 15.1m | 14.2m | 23.0m | 28.7m | 33.7m | 40.6m | 43.0m | 44.8m | 44.9m | |||||
Prepaid Expenses | 3.1m | 3.0m | 2.8m | 2.7m | 3.1m | 1.8m | 2.0m | 1.7m | 1.8m | 951.0k | 1.8m | 2.5m | 3.6m | 3.5m | 2.7m | 3.3m | 5.2m | 10.8m | 6.0m | 6.2m | 10.6m | 14.4m | 16.2m | 13.6m | 20.1m | 19.6m | 15.7m | 18.3m | 15.6m | 21.7m |
Inventories | 194.0k | 3.3m | 3.7m | 3.9m | 7.3m | 8.1m | 7.8m | 6.3m | 8.2m | 10.4m | 9.2m | 12.8m | 13.0m | 15.8m | 18.8m |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | (44.4m) | (48.8m) | (59.6m) | (68.9m) | (132.1m) | (200.0m) | (284.0m) | (349.0m) | (356.4m) | (276.9m) |
Depreciation and Amortization | 1.6m | 1.7m | 1.7m | 1.5m | 1.8m | 3.2m | 3.6m | 4.2m | 4.8m | 8.8m |
Inventories | (3.7m) | (897.0k) | (4.2m) | (5.1m) | (4.6m) | |||||
Accounts Payable | 1.4m | (863.0k) | (613.0k) | 6.2m | 15.5m | 7.1m | 12.6m | 17.1m | 46.7m | (10.6m) |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (26.0m) | (35.7m) | (13.1m) | (22.5m) | (38.8m) | (17.5m) | (32.8m) | (47.4m) | (15.9m) | (30.6m) | (47.7m) | (24.3m) | (51.4m) | (89.2m) | (43.7m) | (94.7m) | (141.4m) | (55.0m) | (103.1m) | (214.8m) | (49.9m) | (111.8m) | (270.9m) | (120.3m) | (204.8m) | (266.7m) | (88.9m) | (141.4m) | (205.5m) | (65.7m) |
Depreciation and Amortization | 864.0k | 1.2m | 420.0k | 862.0k | 1.3m | 439.0k | 889.0k | 1.3m | 412.0k | 808.0k | 1.2m | 508.0k | 861.0k | 1.3m | 673.0k | 1.4m | 2.3m | 823.0k | 1.6m | 2.5m | 969.0k | 1.9m | 3.0m | 991.0k | 2.1m | 3.3m | 1.8m | 3.8m | 6.3m | 1.6m |
Inventories | (207.0k) | (3.5m) | (243.0k) | (351.0k) | (3.4m) | (3.3m) | (3.4m) | (2.0m) | 345.0k | (1.9m) | (2.0m) | (251.0k) | 1.4m | 2.2m | 741.0k | |||||||||||||||
Accounts Payable | (1.3m) | (192.0k) | (1.3m) | (641.0k) | (280.0k) | (2.4m) | 173.0k | (679.0k) | (987.0k) | (155.0k) | 1.2m | (551.0k) | 459.0k | 14.1m | (9.8m) | (8.2m) | (2.9m) | (1.3m) | (4.3m) | 13.0m | (10.3m) | (11.8m) | 3.7m | (8.9m) | 12.5m | 8.7m | (35.3m) | (23.9m) | (23.4m) | (40.2m) |
USD | Q2, 2011 |
---|---|
Financial Leverage | 2 x |
Amicus Therapeutics has 2k Twitter Followers. The number of followers has increased 1.2% month over month and increased 2% quarter over quarter
1k
Tweets
540
Following
2k
Followers
10
Tweets last 30 days
4
Avg. likes per Tweet
100%
Tweets with engagement
C+
76/100
A+
100/100
D
55/100
When was Amicus Therapeutics founded?
Amicus Therapeutics was founded in 2002.
Who are Amicus Therapeutics key executives?
Amicus Therapeutics's key executives are John F. Crowley, Margaret G. McGlynn and Robert Essner.
How many employees does Amicus Therapeutics have?
Amicus Therapeutics has 584 employees.
What is Amicus Therapeutics revenue?
Latest Amicus Therapeutics annual revenue is $260.9 m.
What is Amicus Therapeutics revenue per employee?
Latest Amicus Therapeutics revenue per employee is $446.7 k.
Who are Amicus Therapeutics competitors?
Competitors of Amicus Therapeutics include Modis Therapeutics, Sanofi Genzyme and PhaseBio Pharmaceuticals.
Where is Amicus Therapeutics headquarters?
Amicus Therapeutics headquarters is located at 3675 Market St, Philadelphia.
Where are Amicus Therapeutics offices?
Amicus Therapeutics has offices in Philadelphia, Northbridge, Pointe-Claire, Paris and in 7 other locations.
How many offices does Amicus Therapeutics have?
Amicus Therapeutics has 11 offices.
Receive alerts for 300+ data fields across thousands of companies